BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,130 filers reported holding BAXTER INTL INC in Q1 2022. The put-call ratio across all filers is 1.41 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $1,048,912 | -12.4% | 20,579 | -7.5% | 0.36% | -18.8% |
| Q3 2022 | $1,198,000 | -24.4% | 22,252 | -9.8% | 0.45% | -20.4% |
| Q2 2022 | $1,584,000 | -21.7% | 24,656 | -5.4% | 0.56% | -4.7% |
| Q1 2022 | $2,022,000 | -10.1% | 26,073 | -0.5% | 0.59% | -2.6% |
| Q4 2021 | $2,249,000 | -12.4% | 26,200 | -17.9% | 0.61% | -19.8% |
| Q3 2021 | $2,568,000 | -3.7% | 31,927 | -3.6% | 0.76% | -6.7% |
| Q2 2021 | $2,667,000 | -18.0% | 33,134 | -14.1% | 0.81% | -27.8% |
| Q1 2021 | $3,252,000 | +4.6% | 38,553 | -0.5% | 1.12% | -0.4% |
| Q4 2020 | $3,110,000 | -6.9% | 38,756 | -0.1% | 1.13% | -22.1% |
| Q2 2020 | $3,339,000 | +3.7% | 38,784 | -2.2% | 1.45% | -13.9% |
| Q1 2020 | $3,219,000 | -1.6% | 39,647 | +1.3% | 1.68% | +24.7% |
| Q4 2019 | $3,273,000 | -4.3% | 39,138 | +0.1% | 1.35% | -10.7% |
| Q3 2019 | $3,421,000 | +13.0% | 39,106 | +5.8% | 1.51% | +11.0% |
| Q2 2019 | $3,027,000 | +0.7% | 36,959 | +0.0% | 1.36% | -10.4% |
| Q1 2019 | $3,005,000 | +25.5% | 36,957 | +1.6% | 1.52% | +2.9% |
| Q4 2018 | $2,394,000 | -13.6% | 36,367 | +1.1% | 1.47% | +1.7% |
| Q3 2018 | $2,772,000 | +13.2% | 35,957 | +8.4% | 1.45% | +1.1% |
| Q2 2018 | $2,449,000 | +13.7% | 33,167 | +0.2% | 1.43% | +9.9% |
| Q1 2018 | $2,154,000 | -3.4% | 33,116 | +1.5% | 1.30% | +10.5% |
| Q4 2017 | $2,229,000 | +9.0% | 32,611 | +1.4% | 1.18% | +5.2% |
| Q3 2017 | $2,045,000 | +17.5% | 32,160 | +12.0% | 1.12% | +6.2% |
| Q2 2017 | $1,741,000 | +17.4% | 28,707 | +0.4% | 1.06% | +18.4% |
| Q1 2017 | $1,483,000 | +16.9% | 28,600 | +5.3% | 0.89% | +8.5% |
| Q4 2016 | $1,269,000 | +14.9% | 27,161 | +16.4% | 0.82% | +14.5% |
| Q3 2016 | $1,104,000 | +4.6% | 23,341 | 0.0% | 0.72% | +0.7% |
| Q2 2016 | $1,055,000 | +7.1% | 23,341 | -2.6% | 0.71% | -3.5% |
| Q1 2016 | $985,000 | +6.3% | 23,971 | -1.3% | 0.74% | +5.6% |
| Q4 2015 | $927,000 | +16.2% | 24,286 | 0.0% | 0.70% | +11.5% |
| Q3 2015 | $798,000 | -33.2% | 24,286 | +42.2% | 0.63% | -21.7% |
| Q2 2015 | $1,194,000 | -6.7% | 17,081 | -8.6% | 0.80% | -6.2% |
| Q1 2015 | $1,280,000 | -7.4% | 18,691 | -0.9% | 0.86% | -11.0% |
| Q4 2014 | $1,383,000 | +2.4% | 18,866 | +0.2% | 0.96% | -1.9% |
| Q3 2014 | $1,351,000 | -1.6% | 18,825 | -0.9% | 0.98% | +0.9% |
| Q2 2014 | $1,373,000 | -3.6% | 18,995 | -1.9% | 0.97% | -7.3% |
| Q1 2014 | $1,424,000 | +4.9% | 19,355 | -0.8% | 1.05% | +7.8% |
| Q4 2013 | $1,358,000 | +5.6% | 19,520 | -0.3% | 0.97% | -4.7% |
| Q3 2013 | $1,286,000 | -4.2% | 19,570 | +0.9% | 1.02% | -11.9% |
| Q2 2013 | $1,343,000 | – | 19,395 | – | 1.16% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SECTOR GAMMA AS | 713,500 | $49,895,000 | 12.74% |
| Veritas Asset Management LLP | 7,636,450 | $534,017,000 | 7.53% |
| FIRST NEW YORK SECURITIES LLC /NY | 154,158 | $10,780,269,000 | 5.40% |
| Gabalex Capital Management LLC | 200,000 | $14,981,000 | 5.39% |
| Veritas Investment Management LLP | 291,825 | $18,816,000 | 5.32% |
| Tweedy, Browne Co LLC | 2,543,966 | $177,900,000 | 4.91% |
| York Capital Management Global Advisors, LLC | 8,074,375 | $564,641,000 | 4.78% |
| First Fiduciary Investment Counsel, Inc. | 270,675 | $18,928,000 | 4.10% |
| SCHARF INVESTMENTS, LLC | 2,247,225 | $157,148,000 | 4.03% |
| Osher Van de Voorde Investment Management | 96,235 | $6,730,000 | 3.91% |